HIMS Stock Forecast & Price Target

Hims & Hers Health has experienced a significant increase in its subscriber base, with a 55% year-over-year growth in personalized product memberships, which now constitute approximately 65% of total membership figures for the third quarter of 2025. The company's revenue outlook for FY25 reflects a base of around $50 million, with expectations of international revenue soaring to nearly $1 billion by FY30, driven by enhancements in treatments, geographic expansion, and an improved user experience. Additionally, projected core U.S. revenue growth of approximately 21% annually is supported by increased subscriber numbers and higher revenue per subscriber, indicating a positive trajectory for both top-line and EBITDA growth.

Hims & Hers Health has experienced a notable decline of over 20% in its stock price since late July, despite more than doubling year-to-date, primarily due to concerns regarding slowing core growth. The company faces significant challenges including the slower adoption of personalized treatments, the impact of potential regulatory changes in the healthcare sector, and heightened competition in the digital health space, which could hinder its ability to sustain revenue growth. Additionally, a downturn in the macroeconomic environment may adversely affect consumer spending on direct-to-consumer healthcare subscriptions, further complicating Hims & Hers' financial outlook.